Date receipt dossier
EudraCT number
2016-000632-17
Company / Sponsor
Hookipa Biotech AG
Phase
I
Treated organism
Humans
Indication category
Vaccination
Disease
Cytomegalovirus (CMV) infection
Therapeutic approach
Prevention
Genetic modification
Two replication-deficient lymphocytic choriomeningitidis virus (rLCMV) vectors, one expressing a truncated gBprotein of HCMV and one expressing the pp65 protein of the human CMV
Method of transfer of nucleic acid of interest
Not applicable, rLCMV vectors
Administered biological material
HB-101: Bivalent vaccine containing two recombinant, replication-deficient rLCMV vectors
Route of administration
Intramuscular
Locations in Belgium
UZ Gent
Type of procedure
Contained use only
Current status
Authorized